Stock Events

Stock Events

Inventiva 

$3.65
108
-$0.37-9.2%Friday 08:00

Statistics

Day High
4.06
Day Low
3.64
52W High
5.5
52W Low
2.86
Volume
440
Avg. Volume
-
Mkt Cap
862.26M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Sep 28Expected
Q2 2025
Q4 2025
Q2 2026
-1.91
-1.37
-0.83
-0.29
Expected EPS
-0.41799396
Actual EPS
-0.285515

Financials

-7,881.61%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
5.28MRevenue
-416.46MNet Income

Analyst Ratings

$16.75Average Price Target
The highest estimate is ⁦21.00⁩.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IVA.BOATS. It's not an investment recommendation.
NVIDIA
12
NVDA
BNP Paribas
12
BNP.PA
TotalEnergies
11
TTE.PA
Microsoft
10
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Madrigal Pharmaceuticals
MDGL
Mkt Cap9.94B
Madrigal Pharmaceuticals is involved in developing solutions for nonalcoholic steatohepatitis (NASH), a key area of focus for Inventiva.
Viking Therapeutics
VKTX
Mkt Cap3.48B
Viking Therapeutics is working on treatments for metabolic and endocrine disorders, including NASH, making it a competitor.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences has a broad portfolio that includes treatments for liver diseases, such as NASH, competing with Inventiva's pipeline.
Agenus
AGEN
Mkt Cap308.91M
Agenus Inc. is focused on immuno-oncology but its interest in novel therapeutic approaches can indirectly compete with Inventiva's innovative treatments.
Abbvie
ABBV
Mkt Cap521.11B
AbbVie has a diverse biopharmaceutical portfolio that includes research in fibrosis, making it a competitor.
Pfizer
PFE
Mkt Cap173.95B
Pfizer has a broad research portfolio that includes fibrosis and other areas relevant to Inventiva's interests.
Novartis
NVS
Mkt Cap303.67B
Novartis AG conducts extensive research in areas including fibrosis and metabolic diseases, overlapping with Inventiva's therapeutic areas.

About

Inventiva SA is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with unmet medical needs.
Show More
CEO
ISIN
US46124U1079

Listings

XETRA
DE
6IV.XETRA
STU
DE
6IV.STU
STU
DE
6IVA.STU
MU
DE
6IV.MU

0 Comments

Share your thoughts

FAQs

What is Inventiva stock price today?▼
The current price of IVA.BOATS is $3.65 USD — it has decreased by -9.2% in the past 24 hours. Watch Inventiva stock price performance more closely on the chart.
What is Inventiva stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boats exchange Inventiva stocks are traded under the ticker IVA.BOATS.
What is Inventiva market cap?▼
Today Inventiva has the market capitalization of 862.26M
When is the next Inventiva earnings date?▼
Inventiva is going to release the next earnings report on March 31, 2027.
What were Inventiva earnings last quarter?▼
IVA.BOATS earnings for the last quarter are -0.29 USD per share, whereas the estimation was -0.42 USD resulting in a +31.69% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Inventiva revenue for the last year?▼
Inventiva revenue for the last year amounts to 5.28M USD.
What is Inventiva net income for the last year?▼
IVA.BOATS net income for the last year is -416.46M USD.
In which sector is Inventiva located?▼
Inventiva operates in the Other sector.
When did Inventiva complete a stock split?▼
Inventiva has not had any recent stock splits.